UK separation from the EU could extend wait times for those seeking new, innovative medicines. Brexit will likely include a withdrawal from the European Medicines Agency, the body currently responsible for approving and regulating new drugs. As an individual market, the United Kingdom’s relative size could reduce its attractiveness to drug companies focused on introducing their new products to the largest markets.

Cancer drugs may be delayed after Brexit, say experts – BBC News